MELA Sciences Reports Positive Reception for its Optical Melanoma Diagnostic Device at Clinical Advisory Meeting & Mount Sina...
December 09 2013 - 12:47PM
Business Wire
MELA Sciences, Inc. (NASDAQ: MELA) designer and developer of
MelaFind®, an FDA approved non-invasive optical device that assists
dermatologists in the diagnosis of melanoma, received positive
dermatologist feedback from its second Clinical Advisory Meeting
held in conjunction with the 16th Annual Mount Sinai Winter
Dermatology Symposium last week.
The symposium weekend kicked off with a Clinical Advisory
Meeting featuring ten leading dermatologists, specializing in
melanoma and pigmented skin lesions, who participated in a
roundtable discussion about MelaFind which was moderated by Dr.
Gary Goldenberg. He and Dr. Julie Russak led the meeting with
presentations regarding their MelaFind experiences. Dr. Goldenberg
has been using MelaFind in clinical practice for over a year and
Dr. Russak has incorporated MelaFind evaluations into the patient
care workflow at her thriving Manhattan dermatology practice,
Russak Dermatology Clinic.
Dr. Goldenberg is Assistant Professor, Dermatology and
Pathology, and Medical Director of the Dermatology Faculty Practice
at Mount Sinai. Dr. Russak is a Board Certified Dermatologist, a
Fellow of the American Academy of Dermatology, a member of the
American Society of Dermatologic Surgery, and a Volunteer Faculty
in Dermatology at Mount Sinai Hospital. In addition to extensive
research in Cutaneous Oncology, Dr. Russak edited the July 2012
issue of the Dermatologic Clinic’s update on Melanoma and Pigmented
Lesions.
Dr. Goldenberg commented, “MelaFind has proven to be a valuable
adjunct for me in the process of making a melanoma diagnosis.
Medically, you are doing more for patients in using MelaFind
because the added information it provides puts the physician in a
more informed position than we were in without the device.
Importantly, most patients are relieved when you use MelaFind as
part of their exam because it helps us explain our decisions to
biopsy a lesion or not.”
He added, “Beyond patient care, I believe MelaFind can also be
useful to dermatopathologists. Images and data from the device may
prove valuable in guiding their preparation and review of each
tissue sample, as well as their ability to look deeper and at more
levels in order to render a more accurate diagnosis.”
Dr. Russak explained, “In dermatology, we’ve long had to rely on
the naked eye, without the benefit of diagnostic tools. MelaFind
changes all of that; it is the first of its kind to help us with
diagnosing melanoma. It is particularly suitable for medically
oriented practices that see a volume of high-risk patients.
MelaFind is a fantastic tool when conducting full body skin
exams.”
Dr. Russak added, “When examining patients with many atypical
moles, the information provided by MelaFind is a major help with my
mole management decisions. It is also very useful in examining
young women, a patient population that does not want scars on their
body. The objective data that MelaFind provides 2.5 mm beneath the
surface of the skin has revolutionized the way I perform patient
skin exams.”
MelaFind was recently featured in a The Wall Street Journal
article as a new device that holds promise for confirming a
diagnosis and avoiding unnecessary tests: "The Biggest Mistakes
Doctors Make"
Melanoma – Deadly but Curable if Caught Early
Melanoma is a skin cancer formed in melanocytes, cells
responsible for forming pigments (melanin) responsible for skin
color. Melanoma is the deadliest and fastest growing cancer in the
U.S., according to the Skin Cancer Foundation. Doctors in the
United States diagnose about 160,000 new cases of melanoma per
year, and the World Health Organization estimates about 48,000
melanoma related deaths occur worldwide each year. Melanoma is
almost 100% curable if caught early; however, according to a Harris
Interactive Study commissioned by MELA Sciences, 76% of Americans
have never had a skin check by a dermatologist.
Please follow us:
Twitter: @MELASciencesIR or @MelaFind
StockTwits: @MELASciencesIR
About MELA Sciences, Inc. www.melasciences.com
MELA Sciences is a medical device company developing dermatology
diagnostics utilizing state-of-the-art optical imaging. The
Company’s flagship product is MelaFind®, an FDA approved,
non-invasive diagnostic tool to aid dermatologists in melanoma
evaluation and diagnosis. MelaFind® uses a variety of visible to
near-infrared light waves to evaluate skin lesions from the surface
to 2.5 mm beneath the skin. The device provides images and data on
the relative disorganization of a lesion's cell structure that
provides substantial additional perspective to aid in melanoma
diagnosis. MELA is also exploring new potential uses for its core
imaging technology and algorithms. MelaFind® has also received CE
Mark approval and is approved for use in the European Union.
Safe Harbor
This press release includes "forward-looking statements" within
the meaning of the Securities Litigation Reform Act of 1995. These
statements include but are not limited to our plans, objectives,
expectations and intentions and may contain words such as “seeks,”
“look forward,” and “there seems” that suggest future events or
trends. These statements are based on our current expectations and
are inherently subject to significant uncertainties and changes in
circumstances. Actual results may differ materially from our
expectations due to financial, economic, business, competitive,
market, regulatory and political factors or conditions affecting
the company and the medical device industry in general, as well as
more specific risks and uncertainties set forth in the company’s
SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any
or all of these forward-looking statements may prove to be
incorrect or unreliable. MELA Sciences assumes no duty to update
its forward-looking statements and urges investors to carefully
review its SEC disclosures available at www.sec.gov and
www.melasciences.com.
MediaErica SperlingRpr Marketing
Communications212-317-1462Erica.sperling@rprmc.comorInvestorsToni
Trigiani, David CollinsCatalyst
Global212-924-9800mela@catalyst-ir.com
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Apr 2023 to Apr 2024